Similar articles for PMID: 11090748

Year	Number of Results
1990	1
1991	6
1992	12
1993	19
1994	19
1995	15
1996	21
1997	14
1998	22
1999	26
2000	30
2001	22
2002	20
2003	9
2004	8
2005	8
2006	2
2007	6
2008	6
2009	10
2010	10
2011	7
2012	8
2013	3
2014	1
2015	2
2016	2
2017	1
2019	1
2020	2
2021	4
2022	5
2024	1

1

A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.

Rusconi S, La Seta Catamancio S, Sheridan F, Parker D. Rusconi S, et al. J Clin Virol. 2000 Dec;19(3):135-42. doi: 10.1016/s1386-6532(00)00087-1. J Clin Virol. 2000. PMID: 11090748

2

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P. Sirivichayakul S, et al. AIDS. 2003 Sep 5;17(13):1889-96. doi: 10.1097/00002030-200309050-00007. AIDS. 2003. PMID: 12960821 Clinical Trial.

3

Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.

Gómez-Cano M, Rubio A, Puig T, Pérez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B, Leal M. Gómez-Cano M, et al. AIDS. 1998 Jun 18;12(9):1015-20. AIDS. 1998. PMID: 9662197

4

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA. Miller V, et al. AIDS. 1998 May 7;12(7):705-12. doi: 10.1097/00002030-199807000-00006. AIDS. 1998. PMID: 9619801

5

Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.

Reinis M, Vandasová J, Stanková M, Linka M, Brůcková M. Reinis M, et al. Acta Virol. 2001;45(5-6):279-86. Acta Virol. 2001. PMID: 12083326

6

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.

Ruiz L, Romeu J, Martínez-Picado J, Schmit JC, Vandamme AM, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E, Clotet B. Ruiz L, et al. AIDS. 1996 Dec;10(14):F61-6. doi: 10.1097/00002030-199612000-00003. AIDS. 1996. PMID: 8970679 Clinical Trial.

7

Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.

Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M. Venturi G, et al. Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):274-82. doi: 10.1007/s100960050276. Eur J Clin Microbiol Infect Dis. 1999. PMID: 10385016

8

High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.

Horban A, Stanczak JJ, Bakowska E, Tobolewska EJ, Przybylska-Stengiel KJ, Stanczak GP, Burkacka E. Horban A, et al. Infection. 2002 Dec;30(6):356-9. doi: 10.1007/s15010-002-3055-4. Infection. 2002. PMID: 12478325

9

Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.

Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM; ACTG 303 Study Team. Albrecht MA, et al. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1337-44. doi: 10.1089/08892220050140883. AIDS Res Hum Retroviruses. 2000. PMID: 11018853 Clinical Trial.

10

Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies.

Césaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabié A. Césaire R, et al. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):401-5. doi: 10.1097/00126334-199912010-00012. J Acquir Immune Defic Syndr. 1999. PMID: 10634203

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

312 results

Results by year